Cerebrolysin® Pack
Cerebrolysin® is a multi-modal neuropeptide drug with a fast onset of action that helps to regain and maintain the independence of patients suffering from stroke, TBI, dementia and cognitive impairment. Cerebrolysin® improves the brain’s ability for self-repair by stimulating neurorecovery.
The experience with Cerebrolysin® during many years of clinical application, the information from post-marketing surveillance studies, the safety data from double-blind, placebo-controlled clinical trials demonstrate the excellent clinical safety profile of Cerebrolysin®.
Please note that proper handling of the ampoule is essential to avoid injury or contamination. You can get more information in the Dosage Card.
According to EMA classification (European Medicines Agency), Cerebrolysin® is in the SAFE category. Cerebrolysin® is not approved by the U.S. FDA for any therapeutic or diagnostic use. It is supplied for research only.
This product is for research and educational purposes only. It is not intended for diagnostic or therapeutic use without the guidance of a qualified healthcare professional. Please refer to our terms and conditions prior to purchase.
Safety Information: Keep this product out of the reach of children. This material has limited research available about it and may result in adverse effects if improperly handled or consumed. This product is not a dietary supplement, but a pure substance, sold as a raw material. We attest exclusively to the quality, purity and description of the materials we provide. This product is for use and handling only by persons with the knowledge and equipment to safely handle this material. You agree to indemnify us for any adverse effects that may arise from improper handling and/or consumption of this product.
The articles and information on products that may be found on this website are provided exclusively for the purposes of providing information and education. These items are not pharmaceuticals or medications, and the Food and Drug Administration has not given permission for the treatment or prevention of any disease, medical condition, or ailment using them.
Frequently Asked Questions
Cerebrolysin® Pack
-
Research evidence is one of the key elements of evidence-based clinical decision making, a process, which also takes into account the clinical state and circumstances of the patient and the patient’s preferences. Research evidence on the efficacy and safety of Cerebrolysin® has been established on the basis of randomized controlled double-blind trials (RCTs) and is supported by systematic reviews and meta-analyses, representing the highest quality levels of evidence.
-
Yes, several studies have been performed testing Cerebrolysin® in combination with various standard therapies like tPA or donepezil. Most stroke patients who receive other medication during the acute or sub-acute phase after stroke also receive medications like statins, aspirin, NOACs, etc. No incompabilities have been reported.
-
Generally, the side effects of Cerebrolysin® are rare and of mild intensity. The most frequently reported adverse reactions with Cerebrolysin® are dizziness, headache, sweating, and nausea.
-
Yes, Cerebrolysin® stimulates natural recovery processes after stroke. These processes are most prominent during first 3 months post-stroke. Therefore, Cerebrolysin® can be given within this broad treatment window. Both the research and clinical data for Cerebrolysin® indicate that the best treatment effects are seen when Cerebrolysin® is administered as soon as it is possible after stroke and continued during the natural recovery phase.
-
Cerebrolysin® is not approved for the treatment of depression. However, possible additive effects have been observed when used in combination with anti-depressants or MAO inhibitors.
-
Download the Dosage Card
Handling is very important
Special precautions to avoid contamination and to guarantee sterility must be taken during the dilution and administration of Cerebrolysin®.
- Start the infusion as quickly as possible after removal of the solution from the vials/ampoules.
- Never break ampoule if it will not be administered to the patient yet.
- Always use only disposable one-way IV infusions sets and cannulas.
- Flush the IV infusion set and cannula before and after infusion with 0.9% NaCI solution.
- Cerebrolysin® should not be mixed with other drugs.
- Vitamins and cardiovascular drugs may be given concomitantly with Cerebrolysin® but the drugs should not be mixed with Cerebrolysin®.
-
We're happy to help answer questions you may have. Email us at care@somapeptides.com.